Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused
Click the above link to access the Digital Edition of the April 2015 issue of MM&M, with all text, charts and pictures.
The FDA has to respect First Amendment limitations regulating scientific communication
Robbing pharma to pay Senator Pothole will not encourage innovation
A monthly showcase of companies offering expertise, experience and services within specific areas of the industry. This month: Rare Diseases
Storytellers can both build meaningful story lines out of trend lines and construct rationales from ratios
Sorting out competing priorities is one way to expedite medical-legal review. What should drive work flow—great creative for the brand or need to mitigate risk (compliance, legal, medical, regulatory, brand image)?
MM&M's showcase of healthcare marketing, communications, tech, media and research companies that are helping to shape the future of the industry
Contact information for companies listed in this issue
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
- Lawmakers propose allowing pharma companies to share some off-label information
- US pharma market value projected to be $550 billion in five years
- Everyday Health buys rare-disease agency Cambridge BioMarketing
- Biosimilar uptake will require companies to tell a trustworthy backstory
- Apple's ResearchKit: Five Guidelines for Pharma